55
Participants
Start Date
April 26, 2018
Primary Completion Date
March 15, 2019
Study Completion Date
March 15, 2019
HEC 68498
HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
Placebo
Placebo
Covance Clinical Research Unit, Inc., Daytona Beach
Collaborators (1)
Covance
INDUSTRY
Sunshine Lake Pharma Co., Ltd.
INDUSTRY